Syneos Health (NASDAQ:SYNH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The firm currently has a $41.00 price objective on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 8.04% from the company’s previous close.
According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
Several other analysts have also recently weighed in on SYNH. TheStreet raised Syneos Health from a “c” rating to a “b-” rating in a report on Monday, November 6th. Robert W. Baird cut Syneos Health to an “outperform” rating and dropped their price target for the stock from $67.00 to $46.00 in a report on Friday, November 10th. Jefferies Group reissued a “buy” rating and set a $55.00 price target on shares of Syneos Health in a report on Friday, November 10th. KeyCorp reaffirmed a “market perform” rating and issued a $46.00 price objective (down from $68.00) on shares of Syneos Health in a report on Monday, November 13th. Finally, Credit Suisse Group dropped their price objective on Syneos Health from $68.00 to $54.00 and set an “outperform” rating for the company in a report on Tuesday, November 14th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $48.89.
In other Syneos Health news, CAO Christopher L. Gaenzle sold 1,470 shares of Syneos Health stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $41.00, for a total value of $60,270.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.24% of the stock is owned by insiders.
An institutional investor recently bought a new position in Syneos Health stock. Geode Capital Management LLC purchased a new position in shares of Syneos Health Inc (NASDAQ:SYNH) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 540,604 shares of the company’s stock, valued at approximately $23,570,000. Geode Capital Management LLC owned approximately 0.52% of Syneos Health as of its most recent filing with the SEC. Hedge funds and other institutional investors own 97.49% of the company’s stock.
WARNING: This piece was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://weekherald.com/2018/02/15/syneos-health-synh-stock-rating-upgraded-by-zacks-investment-research.html.
Syneos Health Company Profile
Syneos Health, Inc, formerly INC Research Holdings, Inc, is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.